Stem Cells Market By Product (Adult Stem Cells, Human Embryonic Stem Cells, Induced Pluripotent Stem Cells, Very Small Embryonic Like Stem Cells), By Application (Regenerative Medicine, Drug Discovery And Development), By Therapy (Autologous Stem Cell Therapy, Allogeneic Stem Cell Therapy) - Growth, Future Prospects, And Competitive Analysis, 2017 - 2025

Global Stem Cells Market by Products (Adult Stem Cells, Human Embryonic Stem Cells, Induced Pluripotent Stem Cells, and Very Small Embryonic Like Stem Cells), Applications (Regenerative Medicine, Drug Discovery and Development), and Therapy (Autologous Stem Cells Therapy, Allogenic Stem Cells Therapy), 2017-2025

To accelerate stem cell technology from the perspective of drug discovery and development, the pharmaceutical giants are currently focusing on integrating differentiation pathway discovery in non-human and human systems, developing stem cell training courses and institutional core facilities, and developing stem cell gene-tagged libraries. Furthermore, the cellular models and designs of stem cells used are being optimized, with a special emphasis on euploid, developmentally manipulative human models and probing the mechanistic and phenotypic robustness of natural genetic variation.

For the purpose of this study, the various products studied include adult stem cells, human embryonic stem cells, induced pluripotent stem cells, and very small embryonic-like stem cells. Adult stem cells are further classified as neural stem cells, hematopoietic stem cells, mesenchymal stem cells, umbilical cord stem cells, and others. The applications are classified as regenerative medicines and drug discovery and development. Regenerative medicines are further categorized as those used in neurology, orthopedics, oncology, hematology, cardiovascular diseases, diabetes, liver disorders, and others. The therapy segment is further categorized as autologous stem cell therapy and allogeneic stem cell therapy. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global stem cell market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global stem cell market. The key players profiled in this report are Advanced Cell Technology, Inc., BIOTIME, Inc., BrainStorm Cell Therapeutics, Caladrius, Cellartis AB, Celgene Corporation, CellGenix GmbH, Gamida Cell, Genea BioCells, Lonza, PromoCell GmbH, Pluristem, TiGenix, and Waisman Biomanufacturing.

Based on product, the global stem cell market is categorized into

• Adult stem cells
• Neuronal stem cells
• Hematopoietic stem cells
• Mesenchymal stem cells
• Umbilical cord stem cells
• Others
• Human Embryonic Stem Cells
• Induced pluripotent stem cells
• Very small embryonic cells, like stem cells

The stem cell market is driven by factors such as rising demand for epigenetics for drug discovery and development and the development of cellular models to provide a better understanding of disease mechanisms. In addition, stem cells are a repository of information regarding cellular differentiation, tissue homeostasis, and molecular processes. In 2016, the adult stem cells segment held the largest market share, mainly due to factors such as high compatibility with the human body, low contamination while subculturing, and other advantages, such as avoiding ethical issues associated with the use of other human cells.

Induced pluripotent stem cells will be the fastest-growing market throughout the forecast period of 2017–2025, mostly due to their application in regenerative medicine, drug screening, disease modeling, and organoid generation. The major players in the stem cell market are Advanced Cell Technology, Inc., BIOTIME, Inc., BrainStorm Cell Therapeutics, Caladrius, Cellartis AB, Celgene Corporation, CellGenix GmbH, Gamida Cell, Genea BioCells, Lonza, PromoCell GmbH, Pluristem, TiGenix, and Waisman Biomanufacturing.

Based on application, the global stem cell market is categorized into

Regenerative Medicine

• Neurology
• Orthopedics
• Oncology
• Hematology
• Cardiovascular Diseases
• Diabetes
• Liver Disorders
• Others

Drug Discovery and Development

In 2016, regenerative medicine dominated the market mainly due to factors such as the rising prevalence of chronic diseases requiring immediate medical intervention, and it provided novel opportunities for pharmaceutical companies through the identification of lead candidates and the development of novel drugs.

In addition, there is a supportive regulatory environment for the utilization of stem cells as regenerative medicine. The drug discovery and development segment are anticipated to register faster growth throughout the forecast period of 2017–2025, mainly due to increasing demand for stem cell technology by the pharmaceutical giants to reduce the high attrition rate of late-stage drug candidates and build innovative cellular models. Moreover, the constantly evolving methodologies for the isolation of stem cells have led to the advancement of high-throughput and combinatorial screening technologies, thus supplementing drug discovery and development.

Based on therapy, the global stem cell market is categorized into:

• Autologous Stem Cell Therapy
• Allogenic Stem Cell Therapy

In 2016, the autologous stem cell therapy segment held the largest market share, chiefly due to factors such as high body compatibility and no immunological rejection. Furthermore, it can take place outside of the operating room without the use of anesthesia. The limitations of autologous stem cell therapy are that the patient needs to be in close proximity to the hospital or research center, it is a non-scalable technique, and it enrolls only a small patient population.

Allogeneic stem cell therapy will be the fastest-growing market throughout the forecast period of 2017–2025, primarily due to its application in oncology as it gives the "graft versus cancer" effect in which the donor cells make their own immune cells, which helps in destroying any cancer cells remaining after high-dose treatment. Additionally, the donor could be asked to donate more stem cells and white blood cells whenever required. The limitation of this therapy is the graft-versus-host disease, where the donor immune cells attack the healthy host cells, and the risk of infection, even though the donors are tested before, as the surface of the infection after the allogenic transplant as the host immune system is suppressed due to immunosuppressive drugs.

For the purpose of this study, the global stem cell market is categorized into the following regional and country-specific markets:

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• rest of Latin America

Middle East and Africa

• GCC
• Rest of the Middle East and Africa

In 2016, North America was found to be the largest market for stem cells. The dominance of North America is mainly attributed to the rising prevalence of chronic diseases, enhanced government spending on research and development facilities in healthcare institutions, and an affordable reimbursement scenario. The market growth in Europe is mainly attributed to the rising demand for epigenetics and its application in biomedical science.

The increasing popularity of personalized medication and a large number of clinical trials conducted on the therapeutic application of stem cells in treating hematological disorders, Asia Pacific was observed as the fastest-growing regional segment throughout the forecast period of 2017–2025. Factors that are anticipated to propel market growth are the presence of a geriatric population suffering from chronic diseases requiring immediate medical intervention, technological advancements in the extraction and harvesting of stem cells for therapeutic applications, and a supportive regulatory environment for stem cell products. Moreover, factors such as developing health infrastructure and an untapped market in remote areas with unmet medical needs are going to fuel the rapid growth of the stem cell market in Latin America, the Middle East, and Africa in the near future.

Frequently Asked Question: